Alzheimer’s disease (AD) is a progressing neurodegenerative disorder and the main cause of serious irreversible cognitive decline in elderly people. Visinin-like protein 1 (VILIP-1) is a member of the family of calcium-binding proteins and plays a crucial role in AD pathophysiology. Multiple studies have shown that CSF levels of VILIP-1 are increased in AD patients compared to normal controls, or other neurodegenerative conditions. We searched online databases for studies on the levels of VILIP-1 in the CSF of AD patients in comparison to normal controls, mild cognitive impairment (MCI) patients and Dementia with Lewy bodies (DLB) patients. A total of ten studies were used for the comparison between AD and controls, three studies for the comparison between AD and MCI, two studies for AD and DLB and two studies for the comparison between stable MCI and MCI progressed to AD. We found that VILIP-1 levels are significantly higher in AD compared to normal controls, but not to the other groups, and furthermore, they are significantly higher in patient with MCI progressed to AD, than in stable MCI patients.
This is a preview of subscription content, log in to check access.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Mild cognitive impairment
Mild cognitive impairment progressed to Alzheimer’s disease
Dementia with Lewy bodies
Baloyannis SJ, Mavroudis I, Baloyannis IS et al (2016) Mammillary bodies in Alzheimer's disease: a golgi and electron microscope study. Am J Alzheimers Dis Other Dement 31:247–256
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403
Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt Sinai J Med 77:32–42
Mavroudis IA, Fotiou DF, Adipepe LF et al (2010) Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer's disease. Am J Alzheimers Dis Other Dement 25:585–591
Jack CR Jr, Bennett DA, Blennow K et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539–547
Gozes I (2017) Specific protein biomarker patterns for Alzheimer’s disease: improved diagnostics in progress. EPMA J 8:255–259
Mroczko B, Groblewska M, Zboch M et al (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer’s disease. J Alzheimers Dis 43:1031–1037
Sippy T, Cruz-Martin A, Jeromin A et al (2003) Acute changes in short-term plasticity at synapses with elevated levels of neuronal calcium sensor-1. Nat Neurosci 6:1031–1038
Braunewell K, Riederer P, Spilker C et al (2001) Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord 12:110–116
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 20:13
Polanin JR, Hennessy EA, Tanner-Smith EE (2017) A review of meta-analysis packages in R. J Educ Behav Stat 42:206–242
Zhang H, Ng KP, Therriault J et al (2018) Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. Transl Neurodegener 7:23
Babić Leko M, Borovečki F, Dejanović N et al (2016) Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment. J Alzheimers Dis 50:765–778
Kester MI, Teunissen CE, Sutphen C et al (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther 7:59
Luo X, Hou L, Shi H et al (2013) CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. J Neurochem 127:681–690
Tarawneh R, Lee JM, Ladenson JH et al (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78:709–719
Tarawneh R, D'Angelo G, Macy E et al (2011) Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70:274–285
Muszyński P, Kulczyńska-Przybik A, Borawska R et al (2017) The relationship between markers of inflammation and degeneration in the central nervous system and the blood–brain barrier impairment in Alzheimer's disease. J Alzheimers Dis 59:903–912
Babić Leko M, Willumsen N, Nikolac Perković M et al (2018) Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: a preliminary study in a croatian cohort. Brain Behav 8:e01128
Mroczko B, Groblewska M, Zboch M et al (2015) Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease. J Alzheimers Dis 43:1031–1037
O’Callaghan DW, Haynes LP, Burgoyne RD (2005) High affinity interaction of the N-terminal myristoylation motif of the neuronal calcium sensor protein hippocalcin with phosphatidyl inositol 4,5-bisphosphate. Biochem J 391:231–238
Braunewell KH, Paul B, Altarche-Xifro W et al (2010) Interactions of visinin-like proteins with phosphoinositides. Aust J Chem 63:350–356
Coussen F, Perrais D, Jaskolski F et al (2005) Coassembly of two GluR6 kainate receptor splice variants within a functional protein complex. Neuron 47:555–566
Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363–396
Schnurra I, Bernstein HG, Riederer P et al (2001) The neuronal calcium sensor protein VILIP-1 is associated with amyloid plaques and extracellular tangles in Alzheimer’s disease and promotes cell death and tau phosphorylation in vitro: a link between calcium sensors and Alzheimer’s disease? Neurobiol Dis 8:900–909
Chard PS, Bleakman D, Christakos S et al (1993) Calcium buffering properties of calbindin D28k and parvalbumin in rat sensory neurones. J Physiol 472:341–357
Braunewell KH (2012) The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer’s disease-old wine in new bottle. Front Mol Neurosci 5:1–12
Lee JM, Blennow K, Andreasen N et al (2008) The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 54:1617–1623
Conflict of interest
The authors declare that they have no conflict of interest.
The present study is a meta-analysis of previous studies and therefore no ethical approval needed. All the studies included had taken ethical approval
Statement of human and animal right
The present study were carried out with full respect to human rights.
We confirm that the present study is based on the analysis of other studies which had obtained informed consent for all individuals.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mavroudis, I.A., Petridis, F., Chatzikonstantinou, S. et al. A meta-analysis on the levels of VILIP-1 in the CSF of Alzheimer’s disease compared to normal controls and other neurodegenerative conditions. Aging Clin Exp Res (2020). https://doi.org/10.1007/s40520-019-01458-2
- Alzheimer’s disease biomarkers
- CSF biomarkers